^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    1d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    3d
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | N=90 --> 210
    Enrollment change
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan)
    5d
    STATEsMAN- A Phase 2 trial of SaciTuzumAb TirumotEcan (sac-TMT) in patients with MetastAtic castration resistant prostate cancer (mCRPC) (ACTRN12625001382460)
    P2, N=40, Not yet recruiting, Metro South Hospital and Health Services
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    9d
    OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    13d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    13d
    Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer. (PubMed, Iran J Pharm Res)
    This review summarizes a range of ADCs targeting tumor-associated antigens in ovarian cancer, including mirvetuximab soravtansine (MIRV), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), sacituzumab tirumotecan (SKB-264), PF-06664178, anetumab ravtansine (BAY 94-9343), BMS-986148, DMOT4039A, RC88, lifastuzumab vedotin (DNIB0600A), upifitamab rilsodotin (ABBV-181), ZW220, DMUC4064A, and sofituzumab vedotin (DMUC5754A). The ADCs hold significant potential to reshape the treatment landscape for ovarian cancer by providing targeted therapeutic options. Further research is required to optimize patient selection, address resistance mechanisms, and improve safety profiles.
    Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Elahere (mirvetuximab soravtansine-gynx) • budigalimab (ABBV-181) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan) • anetumab ravtansine (BAY 94-9343) • upifitamab rilsodotin (XMT-1536) • RG7600 • lifastuzumab vedotin (DNIB0600A) • RG7882 • ZW220 • BMS-986148
    16d
    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (clinicaltrials.gov)
    P3, N=1023, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Jiataile (sacituzumab tirumotecan)
    17d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    22d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Merck Sharp & Dohme LLC | N=98 --> 38 | Trial completion date: Jul 2028 --> Mar 2028 | Trial primary completion date: Jul 2028 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    24d
    Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    24d
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Jun 2028 | Trial primary completion date: Oct 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    24d
    Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)